This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-25 and is reviewed periodically as new material appears.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
For example, people with migraine are more likely to become anxious and depressed, but people with anxiety and depression also have a higher risk of becoming affected by migraine. The most frequently reported migraine trigger for women is hormonal variation, followed by stress for both women and men. Disrupted sleep, fasting, missing meals, dehydration, and sensory overstimulation are also commonly reported triggers. There is strong evidence that hormonal changes, stress, quality of sleep, and fasting are causally related to migraine attacks. These "catalyst triggers" may increase activity in the hypothalamus or trigeminal system of the brain until it exceeds the brain's migraine threshold. From puberty onwards, women experience migraine attacks more frequently and with greater severity than men, particularly for migraine without aura. The incidence of attacks of migraine without aura is strongly related to hormonal fluctuations in estrogen, both monthly and across a woman's lifespan. Keeping the body's internal environment stable and consistent appears to protect the brain's migraine sensitivity threshold, while disruption and stresses may make it more likely for the brain to go past its sensitivity threshold. Lifestyle changes that support stability, such as regular sleep, regular meals, and stress management, can help to prevent migraines. Whether a possible trigger is an actual cause or an early symptom, it may be possible to reduce discomfort by managing exposure to sensory stimuli such as smells, lights, sound, or touch.
Two different Dromaius species were present in Australia at the time of European settlement, and one additional species is known from fossil remains. The insular dwarf emus, D. n. baudinianus and D. n. minor, originally present on Kangaroo Island and King Island respectively, both became extinct shortly after the arrival of Europeans. D. n. diemenensis, another insular dwarf emu from Tasmania, became extinct around 1865. The mainland subspecies, D. n. novaehollandiae, remains common. The population of these birds varies from decade to decade, largely being dependent on rainfall; in 2009, it was estimated that there were between 630,000 and 725,000 birds. Emus were introduced to Maria Island off Tasmania, and Kangaroo Island off the coast of South Australia, during the 20th century. The Maria Island population died out in the mid-1990s. The Kangaroo Island birds have successfully established a breeding population. In 1912, the Australian ornithologist Gregory M. Mathews recognised three living subspecies of emu, D. n. novaehollandiae (Latham, 1790), D. n. woodwardi Mathews, 1912 and D. n. rothschildi Mathews, 1912. The Handbook of the Birds of the World, however, argues that the last two of these subspecies are invalid; natural variations in plumage colour and the nomadic nature of the species make it likely that there is a single race in mainland Australia. Examination of the DNA of the King Island emu shows this bird to be closely related to the mainland emu and hence best treated as a subspecies.
== Former chains == A&W Restaurants - defunct in 2004 Burger Machine – now a food stall chain Cindy's - established Tarlac 1972, fastfood chain defunct by 2000s Go Nuts Donuts - defunct in 2020 IHOP - introduced 2014, local branches closed in 2022 Manong Pepe's - Jollibee Food Corporation venture into low cost carinderia style fast food. First store opened in 2007 and all stores closed down in 2011 Teddy's Bigger Burgers
Sources: en.wikipedia.org
triglyceride Also triacylglycerol and triacylglyceride. Any of a class of chemical compounds which are ester derivatives of glycerol, consisting of a glycerol backbone connected to any three fatty acid substituents via ester bonds. Triglycerides are one of three major classes of esters formed by fatty acids in biological systems, along with phospholipids and cholesteryl esters. They are the primary constituent of adipose tissue in vertebrates.
=== Fasted state === When fasting, the activation of lipolysis provides fatty acids as the preferred fuel source for respiration. In the liver β-oxidation of fatty acids fulfills the local energy needs and may lead to ketogenesis (creating ketone bodies out of fatty acids.) The ketone bodies are then used to meet the demands of tissues other than the liver. This inhibition of glucose oxidation at the level of pyruvate dehydrogenase preserves pyruvate and lactate, both of which are gluconeogenic precursors.
The Terek Cossack Host was created in 1577 by free Cossacks resettling from the Volga to the Terek River. Local Terek Cossacks joined this host later. In 1792, the host was included in the Caucasus Line Cossack Host, from which it separated again in 1860, with Vladikavkaz as its capital. In 1916, the population of the host was 255,000, within an area of 1.9 million desyatinas.
Sources: en.wikipedia.org
, perpendicular to both the magnetic field and the velocity vector of the ion itself, in the direction determined by the right-hand rule of cross products and the sign of the charge. The force in the magnetic sector is complicated by the velocity dependence but with the right conditions (uniform velocity for example) ions of different masses will separate physically in space into different beams as with the electric sector.
== Overdose == Overdose symptoms can be confusion, hypotension, and tachycardia, and several fatalities have been reported with concentrations in postmortem blood ranging from 0.1 to 7.0 mg/L compared to non-toxic levels in postmortem blood which can extend to 0.4 mg/kg.
Action and Adventure (Sponsored by PC World) – Shadow of the Colossus Artistic Achievement – Shadow of the Colossus Audio Achievement – Electroplankton Best Game (Sponsored by PC World) – Tom Clancy's Ghost Recon Advanced Warfighter Casual and Social – Buzz!: The BIG Quiz Character – LocoRoco (LocoRoco) Children's – LocoRoco Gameplay (Sponsored by Nokia N-Gage) – Lego Star Wars II: The Original Trilogy Gamers' Award (Sponsored by Nokia N-Gage) – 24: The Mobile Game Innovation – Dr. Kawashima's Brain Training: How Old Is Your Brain? Multiplayer – Dungeons and Dragons Online: Stormreach Original Score – Tomb Raider: Legend Screenplay – Psychonauts Simulation – The Movies Soundtrack – Guitar Hero Sports – Fight Night Round 3 Strategy – Rise and Fall: Civilizations at War Technical Achievement (Sponsored by Skillset) – Tom Clancy's Ghost Recon Advanced Warfighter
== External links == Histology at utmb.edu Histology image: 36_02 at the University of Oklahoma Health Sciences Center - "ureter" Histology image: 37_02 at the University of Oklahoma Health Sciences Center - "urinary bladder" Anatomy Atlases – Microscopic Anatomy, plate 02.24 - "Transitional Epithelium", Ureter Histology at KUMC urinary-renal16 "ureter" www.urothelium.com is an online resource for information about Human Urothelium and the "Biomimetic Urothelium" Archived 2011-02-01 at the Wayback Machine Urothelium at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Histology at qmul.ac.uk Archived 2011-07-21 at the Wayback Machine Diagram at umich.edu Archived 2006-09-10 at the Wayback Machine Histology at wisc.edu Archived 2008-06-10 at the Wayback Machine
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.